Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: A randomized controlled trial

Andrea Z. Lacroix, Ellen W. Freeman, Joseph Larson, Janet Carpenter, Hadine Joffe, Susan D. Reed, Katherine M. Newton, Rebecca A. Seguin, Barbara Sternfeld, Lee Cohen, Kristine E. Ensrud

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: To evaluate the effects of escitalopram 10-20 mg/day on menopause-related quality of life and pain in healthy menopausal women with hot flashes. Study design: A double-blind, placebo-controlled randomized trial of escitalopram 10-20 mg/day vs. identical placebo was conducted among 205 women ages 40-62 years with an average of ≥4 daily hot flashes recruited at 4 clinical sites from July 2009 to June 2010. Main outcome measures: The primary trial outcomes, reported previously, were the frequency and severity of vasomotor symptoms at 8 weeks. Here, we report on the pre-specified secondary endpoints of total and domain scores from the Menopause-Specific Quality of Life Questionnaire (MENQOL) and the pain intensity and interference scale (PEG). Results: Outcome data were collected on 97% of randomized women and 87% of women took at least 70% of their study medication. Treatment with escitalopram resulted in significantly greater improvement in total MENQOL scores (mean difference at 8 weeks of -0.41; 95% confidence interval (CI) -0.71 to -0.11; p < 0.001), as well as Vasomotor, Psychosocial, and Physical domain scores with the largest difference seen in the Vasomotor domain (mean difference -0.75; 95% CI -1.28 to -0.22; p = 0.02). There was no significant treatment group difference for the Sexual Function domain. Escitalopram treatment resulted in statistically significant improvements in PEG scores compared to placebo (mean treatment group difference at 8 weeks of -0.33; 95% CI -0.81 to 0.15; p = 0.045). Conclusions: Treatment with escitalopram 10-20 mg/day in healthy women with vasomotor symptoms significantly improved menopause-related quality of life and pain.

Original languageEnglish
Pages (from-to)361-368
Number of pages8
JournalMaturitas
Volume73
Issue number4
DOIs
StatePublished - Dec 2012

Fingerprint

Hot Flashes
Citalopram
Menopause
Randomized Controlled Trials
Quality of Life
Pain
Placebos
Confidence Intervals
Polyethylene glycols
Therapeutics
Outcome Assessment (Health Care)

Keywords

  • Antidepressants
  • Escitalopram
  • Menopausal quality of life
  • Randomized controlled trial
  • Vasomotor symptoms

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes : A randomized controlled trial. / Lacroix, Andrea Z.; Freeman, Ellen W.; Larson, Joseph; Carpenter, Janet; Joffe, Hadine; Reed, Susan D.; Newton, Katherine M.; Seguin, Rebecca A.; Sternfeld, Barbara; Cohen, Lee; Ensrud, Kristine E.

In: Maturitas, Vol. 73, No. 4, 12.2012, p. 361-368.

Research output: Contribution to journalArticle

Lacroix, AZ, Freeman, EW, Larson, J, Carpenter, J, Joffe, H, Reed, SD, Newton, KM, Seguin, RA, Sternfeld, B, Cohen, L & Ensrud, KE 2012, 'Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: A randomized controlled trial', Maturitas, vol. 73, no. 4, pp. 361-368. https://doi.org/10.1016/j.maturitas.2012.09.006
Lacroix, Andrea Z. ; Freeman, Ellen W. ; Larson, Joseph ; Carpenter, Janet ; Joffe, Hadine ; Reed, Susan D. ; Newton, Katherine M. ; Seguin, Rebecca A. ; Sternfeld, Barbara ; Cohen, Lee ; Ensrud, Kristine E. / Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes : A randomized controlled trial. In: Maturitas. 2012 ; Vol. 73, No. 4. pp. 361-368.
@article{86f11b9c46bf46b0b19fdf884b711c82,
title = "Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: A randomized controlled trial",
abstract = "Objective: To evaluate the effects of escitalopram 10-20 mg/day on menopause-related quality of life and pain in healthy menopausal women with hot flashes. Study design: A double-blind, placebo-controlled randomized trial of escitalopram 10-20 mg/day vs. identical placebo was conducted among 205 women ages 40-62 years with an average of ≥4 daily hot flashes recruited at 4 clinical sites from July 2009 to June 2010. Main outcome measures: The primary trial outcomes, reported previously, were the frequency and severity of vasomotor symptoms at 8 weeks. Here, we report on the pre-specified secondary endpoints of total and domain scores from the Menopause-Specific Quality of Life Questionnaire (MENQOL) and the pain intensity and interference scale (PEG). Results: Outcome data were collected on 97{\%} of randomized women and 87{\%} of women took at least 70{\%} of their study medication. Treatment with escitalopram resulted in significantly greater improvement in total MENQOL scores (mean difference at 8 weeks of -0.41; 95{\%} confidence interval (CI) -0.71 to -0.11; p < 0.001), as well as Vasomotor, Psychosocial, and Physical domain scores with the largest difference seen in the Vasomotor domain (mean difference -0.75; 95{\%} CI -1.28 to -0.22; p = 0.02). There was no significant treatment group difference for the Sexual Function domain. Escitalopram treatment resulted in statistically significant improvements in PEG scores compared to placebo (mean treatment group difference at 8 weeks of -0.33; 95{\%} CI -0.81 to 0.15; p = 0.045). Conclusions: Treatment with escitalopram 10-20 mg/day in healthy women with vasomotor symptoms significantly improved menopause-related quality of life and pain.",
keywords = "Antidepressants, Escitalopram, Menopausal quality of life, Randomized controlled trial, Vasomotor symptoms",
author = "Lacroix, {Andrea Z.} and Freeman, {Ellen W.} and Joseph Larson and Janet Carpenter and Hadine Joffe and Reed, {Susan D.} and Newton, {Katherine M.} and Seguin, {Rebecca A.} and Barbara Sternfeld and Lee Cohen and Ensrud, {Kristine E.}",
year = "2012",
month = "12",
doi = "10.1016/j.maturitas.2012.09.006",
language = "English",
volume = "73",
pages = "361--368",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",
number = "4",

}

TY - JOUR

T1 - Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes

T2 - A randomized controlled trial

AU - Lacroix, Andrea Z.

AU - Freeman, Ellen W.

AU - Larson, Joseph

AU - Carpenter, Janet

AU - Joffe, Hadine

AU - Reed, Susan D.

AU - Newton, Katherine M.

AU - Seguin, Rebecca A.

AU - Sternfeld, Barbara

AU - Cohen, Lee

AU - Ensrud, Kristine E.

PY - 2012/12

Y1 - 2012/12

N2 - Objective: To evaluate the effects of escitalopram 10-20 mg/day on menopause-related quality of life and pain in healthy menopausal women with hot flashes. Study design: A double-blind, placebo-controlled randomized trial of escitalopram 10-20 mg/day vs. identical placebo was conducted among 205 women ages 40-62 years with an average of ≥4 daily hot flashes recruited at 4 clinical sites from July 2009 to June 2010. Main outcome measures: The primary trial outcomes, reported previously, were the frequency and severity of vasomotor symptoms at 8 weeks. Here, we report on the pre-specified secondary endpoints of total and domain scores from the Menopause-Specific Quality of Life Questionnaire (MENQOL) and the pain intensity and interference scale (PEG). Results: Outcome data were collected on 97% of randomized women and 87% of women took at least 70% of their study medication. Treatment with escitalopram resulted in significantly greater improvement in total MENQOL scores (mean difference at 8 weeks of -0.41; 95% confidence interval (CI) -0.71 to -0.11; p < 0.001), as well as Vasomotor, Psychosocial, and Physical domain scores with the largest difference seen in the Vasomotor domain (mean difference -0.75; 95% CI -1.28 to -0.22; p = 0.02). There was no significant treatment group difference for the Sexual Function domain. Escitalopram treatment resulted in statistically significant improvements in PEG scores compared to placebo (mean treatment group difference at 8 weeks of -0.33; 95% CI -0.81 to 0.15; p = 0.045). Conclusions: Treatment with escitalopram 10-20 mg/day in healthy women with vasomotor symptoms significantly improved menopause-related quality of life and pain.

AB - Objective: To evaluate the effects of escitalopram 10-20 mg/day on menopause-related quality of life and pain in healthy menopausal women with hot flashes. Study design: A double-blind, placebo-controlled randomized trial of escitalopram 10-20 mg/day vs. identical placebo was conducted among 205 women ages 40-62 years with an average of ≥4 daily hot flashes recruited at 4 clinical sites from July 2009 to June 2010. Main outcome measures: The primary trial outcomes, reported previously, were the frequency and severity of vasomotor symptoms at 8 weeks. Here, we report on the pre-specified secondary endpoints of total and domain scores from the Menopause-Specific Quality of Life Questionnaire (MENQOL) and the pain intensity and interference scale (PEG). Results: Outcome data were collected on 97% of randomized women and 87% of women took at least 70% of their study medication. Treatment with escitalopram resulted in significantly greater improvement in total MENQOL scores (mean difference at 8 weeks of -0.41; 95% confidence interval (CI) -0.71 to -0.11; p < 0.001), as well as Vasomotor, Psychosocial, and Physical domain scores with the largest difference seen in the Vasomotor domain (mean difference -0.75; 95% CI -1.28 to -0.22; p = 0.02). There was no significant treatment group difference for the Sexual Function domain. Escitalopram treatment resulted in statistically significant improvements in PEG scores compared to placebo (mean treatment group difference at 8 weeks of -0.33; 95% CI -0.81 to 0.15; p = 0.045). Conclusions: Treatment with escitalopram 10-20 mg/day in healthy women with vasomotor symptoms significantly improved menopause-related quality of life and pain.

KW - Antidepressants

KW - Escitalopram

KW - Menopausal quality of life

KW - Randomized controlled trial

KW - Vasomotor symptoms

UR - http://www.scopus.com/inward/record.url?scp=84869081064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869081064&partnerID=8YFLogxK

U2 - 10.1016/j.maturitas.2012.09.006

DO - 10.1016/j.maturitas.2012.09.006

M3 - Article

C2 - 23031421

AN - SCOPUS:84869081064

VL - 73

SP - 361

EP - 368

JO - Maturitas

JF - Maturitas

SN - 0378-5122

IS - 4

ER -